Evidence map›Paper›PMID 26848149›Full record

ReviewEuropean heart journal2017

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.

Hans-Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, Günter Breithardt, John Eikelboom, Michael D Ezekowitz, Christopher B Granger, Jonathan L Halperin, Stefan H Hohnloser and 6 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. New onset of chest pain: the importance of remote monitoring.European heart journal supplements : journal of the European Society of Cardiology · 2019
    Article
  13. Oral Anticoagulation.Deutsches Arzteblatt international · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 6 countries.

Hans-Christoph DienerDepartment of Neurology, University Hospital Essen, Essen, Germany.
James AisenbergIcahn School of Medicine at Mount Sinai, New York, USA.
Jack AnsellHofstra North Shore/LIJ School of Medicine, Hempstead, USA.
Dan AtarDivision of Medicine, Oslo University Hospital, Ullevål and University of Oslo, Oslo, Norway.
Günter BreithardtDivision of Rhythmology, Department of Cardiovascular Medicine, Hospital of the University Münster, Münster, Germany.
John EikelboomPopulation Health Research Institute, McMaster University, Hamilton, ON, Canada.
Michael D EzekowitzCardiovascular Research Foundation, New York, NY, USA.
Christopher B GrangerDepartment of Medicine, Duke University, Durham, NC, USA.
Jonathan L HalperinIcahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, New York, NY, USA.
Stefan H HohnloserDivision of Clinical Electrophysiology, Department of Cardiology, J. W. Goethe University, Frankfurt, Germany.
Elaine M HylekBoston Medical Center, Boston University School of Medicine, Boston, MA, USA.
Paulus KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, SWBH and UHB NHS Trusts, Birmingham, UK.
Deirdre A LaneUniversity of Birmingham, Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.
Freek W A VerheugtAfdeling Cardiologie, Hartcentrum OLVG, Amsterdam, The Netherlands.
Roland VeltkampStroke Medicine, Imperial College London, London, UK.
Gregory Y H LipUniversity of Birmingham, Birmingham, UK.
Icahn School of Medicine at Mount Sinai · USUniversity Hospital Münster · DEAalborg University · DKBoston Medical Center · USDuke University · USEssen University Hospital · DEGoethe University Frankfurt · DEHofstra University · USImperial College London · GBLankenau Medical Center · USPopulation Health Research Institute · CAUniversity of Birmingham · GBUniversity of Oslo · NO

Funding

British Heart Foundation FS/13/43/30324
6 · The paper itself

Abstract

Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral anticoagulants (NOACs) were compared with warfarin in large randomized trials for the prevention of stroke and systemic embolism. Today's clinician is faced with the difficult task of selecting a suitable OAC for a patient with a particular clinical profile or a particular pattern of risk factors and concomitant diseases. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. NOACs for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In the first of a two-part review, we discuss the choice of NOAC for stroke prevention in the following subgroups of patients with AF: (i) stable coronary artery disease or peripheral artery disease, including percutaneous coronary intervention with stenting and triple therapy; (ii) cardioversion, ablation and anti-arrhythmic drug therapy; (iii) mechanical valves and rheumatic valve disease, (iv) patients with time in therapeutic range of >70% on warfarin; (v) patients with a single stroke risk factor (CHA2DS2VASc score of 1 in males, 2 in females); and (vi) patients with a single first episode of paroxysmal AF. Although there are no major differences in terms of efficacy and safety between the NOACs for some clinical scenarios, in others we are able to suggest that particular drugs and/or doses be prioritized for anticoagulation.

Indexed as

Administration, OralAnticoagulantsAtrial FibrillationCardiac Resynchronization TherapyCatheter AblationClinical Decision-MakingContraindications, DrugCoronary Artery DiseaseDrug Administration ScheduleElectric CountershockHeart Valve DiseasesHeart Valve ProsthesisHumansPercutaneous Coronary InterventionPeripheral Arterial DiseaseRandomized Controlled Trials as TopicAnticoagulantsAnticoagulationNon-valvular atrial fibrillationNon-vitamin-K oral antagonistStroke prevention

Identifiers

PMID26848149
PMCPMC5837588
OpenAlexW2255223807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.